Cargando…

AMPK activation induced in pemetrexed‐treated cells is associated with development of drug resistance independently of target enzyme expression

Pemetrexed (PEM) inhibits DNA and RNA synthesis and is currently one of the first‐line agents for mesothelioma. PEM suppresses the activities of several enzymes involved in purine and pyrimidine synthesis, and elevated activity of these enzymes in tumors is often linked with resistance to PEM. The a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Yiyang, Sekine, Ikuo, Hanazono, Michiko, Morinaga, Takao, Fan, Mengmeng, Takiguchi, Yuichi, Tada, Yuji, Shingyoji, Masato, Yamaguchi, Naoto, Tagawa, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547620/ https://www.ncbi.nlm.nih.gov/pubmed/31033201 http://dx.doi.org/10.1002/1878-0261.12496

Ejemplares similares

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
por: Qin, Yiyang, et al.
Publicado: (2017)

An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced
por: Morinaga, Takao, et al.
Publicado: (2017)

An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression
por: Nguyen, Thao Thi Thanh, et al.
Publicado: (2021)

Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways
por: Shimazu, Kengo, et al.
Publicado: (2017)

Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells
por: Li, Quanhai, et al.
Publicado: (2013)

An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol
por: Tada, Yuji, et al.
Publicado: (2016)

Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma
por: Jiang, Yuanyuan, et al.
Publicado: (2016)

A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene
por: Tada, Yuji, et al.
Publicado: (2015)

Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity
por: Chai, Kuan, et al.
Publicado: (2018)

Role of Membrane Cholesterol Levels in Activation of Lyn upon Cell Detachment
por: Morinaga, Takao, et al.
Publicado: (2018)

Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression
por: Yang, Shan, et al.
Publicado: (2015)

Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes
por: Yamauchi, Suguru, et al.
Publicado: (2017)

Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin on Mesothelioma by Increasing p53 Expression Levels
por: Okamoto, Shinya, et al.
Publicado: (2013)

Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions
por: Okamoto, S, et al.
Publicado: (2014)

Fas Ligand DNA Enhances a Vaccination Effect by Coadministered DNA Encoding a Tumor Antigen through Augmenting Production of Antibody against the Tumor Antigen
por: Zhong, Boya, et al.
Publicado: (2015)

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation
por: KURIMOTO, RYOTA, et al.
Publicado: (2016)

Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured
por: Suzuki, Takeo, et al.
Publicado: (2014)

A Potential Therapeutic Strategy for Malignant Mesothelioma with Gene Medicine
por: Tada, Yuji, et al.
Publicado: (2013)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Pemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven Case
por: Otoshi, Ryota, et al.
Publicado: (2019)

Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG‐TR)
por: Sakai, Kazuko, et al.
Publicado: (2020)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China
por: Ma, Guangyu, et al.
Publicado: (2009)

A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects
por: Tagawa, Masatoshi, et al.
Publicado: (2011)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Effect of renal function on pemetrexed-induced haematotoxicity
por: Ando, Yosuke, et al.
Publicado: (2016)

Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line
por: KITAZONO, SATORU, et al.
Publicado: (2013)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

Recruitment of Lyn from endomembranes to the plasma membrane through calcium-dependent cell-cell interactions upon polarization of inducible Lyn-expressing MDCK cells
por: Morinaga, Takao, et al.
Publicado: (2017)

Pemetrexed for epithelioid haemangioendothelioma of the pleura
por: Kanemura, Shingo, et al.
Publicado: (2016)

Protective role for lipid modifications of Src-family kinases against chromosome missegregation
por: Honda, Takuya, et al.
Publicado: (2016)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
por: Kasai, Takashi, et al.
Publicado: (2023)

Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
por: Okimoto, Tamio, et al.
Publicado: (2020)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015
por: Kozuki, Toshiyuki, et al.
Publicado: (2016)

Eyelid and feet edema induced by pemetrexed
por: Kastalli, Sarrah, et al.
Publicado: (2016)

Nephrotoxicity in a Patient Treated with Pemetrexed
por: Zajjari, Y., et al.
Publicado: (2017)

Pemetrexed Induced Life-threatening Anaphylaxis
por: Rajasurya, Venkat, et al.
Publicado: (2019)

Edema of the face and extremities secondary to pemetrexed
por: Doyle, Thomas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ep2gufkashg7itndujaabpl2h5